Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 2/20 | 0.59 |
| ▸ | F13A1 | P00488 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TGM1 | P22735 | 1/20 | 0.44 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | CDK13 | Q14004 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CDK7 | P50613 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2099046 | 0.80 | KDM4E (0.47) | LMNANPC1FPR2CYP2C19KMT2A | |
| SCHEMBL15819917 | 0.79 | NPSR1 (0.51) | NPC1FPR2KMT2AALDH1A1KDM4E | |
| SCHEMBL19739532 | 0.76 | FPR2 (0.43) | NPC1FPR2KMT2AALDH1A1KDM4E | |
| SCHEMBL29806233 | 0.76 | FPR2 (0.43) | NPC1FPR2KMT2AALDH1A1KDM4E | |
| SCHEMBL12874091 | 0.75 | FPR2 (0.42) | NPC1FPR2KMT2AALDH1A1KDM4E | |
| SCHEMBL12492927 | 0.75 | FPR2 (0.42) | LMNANPC1FPR2KMT2AALDH1A1 | |
| SCHEMBL8966436 | 0.75 | TGM2 (1.00) | TGM2F13A1LMNATGM1TGM3 | |
| SCHEMBL30448897 | 0.74 | ALDH1A1 (0.68) | LMNANPC1KMT2AALDH1A1KDM4E | |
| SCHEMBL10193856 | 0.74 | ALDH1A1 (0.68) | LMNANPC1KMT2AALDH1A1KDM4E | |
| SCHEMBL17338750 | 0.74 | FPR2 (0.52) | LMNANPC1FPR2KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331023-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2025-06-17 | — | — | US | disclosed |
| EP-3302448-B1 | SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS | AURIGENE ONCOLOGY LTD (IN) | 2023-10-25 | — | — | EP | disclosed |
| EP-3302448-B1 | SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS | AURIGENE ONCOLOGY LTD (IN) | 2023-10-25 | — | — | EP | disclosed |
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | US | disclosed |
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | US | disclosed |
| US-20220098156-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-03-31 | — | — | US | disclosed |
| CN-113773257-A | Substituted heterocyclic derivatives as CDK inhibitors | 奥瑞基尼探索技术有限公司 | 2021-12-10 | — | — | CN | disclosed |
| US-11174232-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-11-16 | — | — | US | disclosed |
| US-11174232-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-11-16 | — | — | US | disclosed |
| CN-108024970-B | Substituted heterocyclic derivatives as CDK inhibitors | 奥瑞基尼探索技术有限公司 | 2021-10-01 | — | — | CN | disclosed |
| US-20200262793-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2020-08-20 | — | — | US | disclosed |
| US-20200262793-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2020-08-20 | — | — | US | disclosed |
| US-10689347-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2020-06-23 | — | — | US | disclosed |
| US-10689347-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2020-06-23 | — | — | US | disclosed |
| US-20180362471-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-12-20 | — | — | US | disclosed |
| US-20180155293-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-06-07 | — | — | US | disclosed |
| US-20180155293-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-06-07 | — | — | US | disclosed |
| EP-3302448-A1 | SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016193939-A1 | SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016193939-A1 | SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK9, CDK1 | TGM2 3352/4885F13A1 2592/4885LMNA 1304/4885 |
| US-11174232-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | CDK19, CDK9, CDK1 | TGM2 3352/4885F13A1 2592/4885LMNA 1304/4885 |
| US-20180362471-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK17, CDK1 | TGM2 3139/4885F13A1 2314/4885LMNA 1389/4885 |
| US-20180155293-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK17, CDK1 | TGM2 3139/4885F13A1 2314/4885LMNA 1389/4885 |
| US-10689347-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | CDK19, CDK9, CDK1 | TGM2 3352/4885F13A1 2592/4885LMNA 1304/4885 |
| US-12331023-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | CDK19, CDK9, CDK1 | TGM2 3352/4885F13A1 2592/4885LMNA 1304/4885 |
| US-20200262793-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK9, CDK1 | TGM2 3352/4885F13A1 2592/4885LMNA 1304/4885 |
| US-20220098156-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK9, CDK1 | TGM2 3352/4885F13A1 2592/4885LMNA 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.